LEXARIA BIOSCIENCE CORP (LEXX) Stock Price & Overview
NASDAQ:LEXX • US52886N4060
Current stock price
The current stock price of LEXX is 0.9558 USD. Today LEXX is down by -3.45%. In the past month the price increased by 39.34%. In the past year, price decreased by -26.38%.
LEXX Key Statistics
- Market Cap
- 23.694M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.47
- Dividend Yield
- N/A
LEXX Stock Performance
LEXX Stock Chart
LEXX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LEXX. When comparing the yearly performance of all stocks, LEXX is a bad performer in the overall market: 76.78% of all stocks are doing better.
LEXX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LEXX. The financial health of LEXX is average, but there are quite some concerns on its profitability.
LEXX Earnings
On April 13, 2026 LEXX reported an EPS of -0.06 and a revenue of 20.00K. The company beat EPS expectations (38.08% surprise) and missed revenue expectations (-60.78% surprise).
LEXX Forecast & Estimates
7 analysts have analysed LEXX and the average price target is 4.59 USD. This implies a price increase of 380.23% is expected in the next year compared to the current price of 0.9558.
For the next year, analysts expect an EPS growth of 43.51% and a revenue growth -70.1% for LEXX
LEXX Groups
Sector & Classification
LEXX Financial Highlights
Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 18.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -178.37% | ||
| ROE | -219.69% | ||
| Debt/Equity | 0 |
LEXX Ownership
LEXX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.8 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.77 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.08 | 289.223B | ||
| PFE | PFIZER INC | 9.18 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.91 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 28.443B | ||
| VTRS | VIATRIS INC | 5.99 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.49 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LEXX
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Company Info
IPO: 2009-10-28
LEXARIA BIOSCIENCE CORP
100 - 740 Mccurdy Road
Kelowna BRITISH COLUMBIA V1X 2P7 CA
CEO: Christopher Bunka
Employees: 7
Phone: 12507656424
LEXARIA BIOSCIENCE CORP / LEXX FAQ
Can you describe the business of LEXARIA BIOSCIENCE CORP?
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
What is the current price of LEXX stock?
The current stock price of LEXX is 0.9558 USD. The price decreased by -3.45% in the last trading session.
Does LEXARIA BIOSCIENCE CORP pay dividends?
LEXX does not pay a dividend.
How is the ChartMill rating for LEXARIA BIOSCIENCE CORP?
LEXX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about LEXARIA BIOSCIENCE CORP (LEXX) stock?
7 analysts have analysed LEXX and the average price target is 4.59 USD. This implies a price increase of 380.23% is expected in the next year compared to the current price of 0.9558.
Who owns LEXARIA BIOSCIENCE CORP?
You can find the ownership structure of LEXARIA BIOSCIENCE CORP (LEXX) on the Ownership tab.
Can you provide the short interest for LEXX stock?
The outstanding short interest for LEXARIA BIOSCIENCE CORP (LEXX) is 1.21% of its float.